Type 2 Diabetes Mellitus: Update Bulletin [Jan 2016]
Gain new KOL insights on the latest events happening in type 2 diabetes mellitus (T2DM): the future of inhaled insulin in the light of the licensing agreement termination between Sanofi and MannKind Corp for Afrezza; Sanofi’s once-daily fixed-dose combination (FDC), LixiLan (insulin glargine and lixisenatide), and how it compares with Novo Nordik’s Xultophy (insulin degludec plus liraglutide); Novo Nordisk’s investigational long acting glucagon-like peptide-1(GLP-1) agonist, semaglutide; KOLs provide insight on Eli Lilly’s recently launched long acting GLP-1 agonist, Trulicity (dulaglutide) and the potential of GLP-1/insulin combinations and discuss the likely impact of the launch of Eli Lilly’s biosimilar insulin glargine (Basaglar/Abasaglar).
Key Questions Answered in this Update Bulletin:
Key Questions Answered in this Update Bulletin:
- What do KOLs think about the future of inhaled insulin following the termination of Sanofi’s licensing agreement with MannKind for Afrezza?
- What are KOLs opinions of pipeline long-acting injectable GLP-1 agonists, Eli Lilly’s Trulicity (dulaglutide) and Novo Nordisk’s Phase III product, semaglutide?
- What factors will drive the uptake of injectable GLP-1 antagonists as greater choice within this therapy class emerges, and what barriers will this class continue to face?
- What concerns do KOLs have Sanofi’s LixiLan (insulin glargine and the GLP-1, lixisenatide fixed dose combination)?
- Where are the potential opportunities for basal insulin/GLP-1 combinations and what are the critical strategic considerations?
- How is Eli Lilly’s Basaglar/Abasaglar likely to impact on the use of current basal insulins such as Sanofi’s Lantus, Novo Nordisk’s Tresiba (insulin degludec) and Sanofi’s Toujeo?
